SharpX destroys pen needles and syringes in seconds via electric incineration — eliminating biohazard risk at the source, for clinics and homes alike. No sharps containers. No liability. No waste.
The Problem
Syringes and needles are essential for vaccines, IV therapy, chemotherapy, GLP-1s, and lab draws — but once used, they become one of healthcare's most expensive waste streams. Regulated medical waste costs many times more per pound than standard trash, creating a permanently high-cost disposal burden that facilities cannot escape.
Every vaccine, IV line, chemotherapy session, and lab draw generates sharps waste. As procedure volumes grow, so does the disposal burden — with no end in sight under the current model.
Regulated medical waste is disposed of at many times the cost of standard trash. Sharps containers, scheduled pickups, and biohazard handling fees create a permanently high and unpredictable expense for every facility.
U.S. hospitals report hundreds of thousands of sharps-related injuries annually. Global estimates exceed 2 million occupational needlestick exposures per year — many unreported — costing hundreds to thousands of dollars each in testing, prophylaxis, and lost staff time.
OSHA, EPA, and state regulations impose strict sharps handling requirements. Non-compliance carries significant fines and legal exposure — and with injury rates this high, facilities can't afford to rely on the status quo.
Our Solution
SharpX uses battery-powered electric incineration to convert used needles into ash in seconds. No exposed metal remains. EPA compliant. Safe for normal trash disposal per local rules. Built for clinics — and now, for home.
Simple battery-powered operation destroys pen needles and syringes completely — no sharps, no biohazard material, no special disposal required. Just ash.
SharpX is designed to meet EPA compliance standards for sharps disposal, mitigating biohazard risk and making working in healthcare safe and sustainable.
A compact, quiet countertop device purpose-built for the 13.5M Americans self-injecting at home. Positioned as a connected, reimbursable DME benefit for payers, GLP-1 manufacturers, and diabetes programs.
Market Opportunity
The self-injection device market is growing rapidly, driven by obesity, diabetes, and biologic therapies. GLP-1 drugs alone are on track for $100–200B in annual sales by 2030–33. Every patient who self-injects is a SharpX user. The U.S. home needle and syringe market already stands at $800M–$1B before fully accounting for GLP-1 growth.
Payers and municipalities bear downstream costs from community needlesticks, ED visits, and waste handling — making SharpX a reimbursable solution with institutional tailwinds behind it.
Cost Savings
SharpX replaces unpredictable sharps container and disposal fees with a flat monthly subscription covering the device and consumables. Most clients are cash-flow positive in the very first month compared to their current waste spend.
Because it's a simple operating expense, payments may be eligible as a tax-deductible business cost — reducing overhead further at year-end. For home users, we're positioning SharpX as a DME / sharps-management benefit that payers and GLP-1 manufacturers can subsidize.
Angel Investment Round
SharpX is positioned at the intersection of two massive growth curves — the GLP-1 explosion and the global push for safer at-home injection. We are raising our angel round to accelerate manufacturing, distribution, and payer partnerships. Join us early.
Express your interest in our current angel round. We'll follow up with our investment deck, financials, and next steps for qualified investors.
Interested in adding SharpX to your clinic, hospital, pharmacy, or home care program? Tell us about your situation and we'll reach out to discuss fit, pricing, and next steps.